|
Thursday, February 24, 2022 |
|
 |
What’s New in Antimicrobials Used in the ICU? Wendy Sligl, MD Professor, Critical Care Medicine and Infectious Diseases, University of Alberta, Edmonton, AB, Canada Dr. Wendy Sligl is Professor in the Department of Critical Care Medicine and Division of Infectious Diseases at the University of Alberta. She practices in the ICU as well as General and Transplant Infectious Diseases. She has a Master’s of Science in Epidemiology and is a Clinician Scientist with interests in sepsis, pneumonia, bloodstream infections, respiratory viral infections and infections in the immune compromised host. |
 |
Antimicrobial Stewardship in the Face of Suspected Sepsis Sameer Kadri, MD Staff ICU Physician and Head, Clinical Epidemiology Section, Clinical Center, NIH Dr. Kadri is a Critical Care and ID physician-investigator at the NIH and heads Clinical Epidemiology in the Critical Care Dept at NIH. He serves as Associate Editor of Critical Care Medicine. |
 |
What’s New in Antimicrobial Resistance in the ICU? Andre Kalil, MD Professor, Department of Internal Medicine and Director, Transplant Infectious Diseases, University of Nebraska, Omaha Dr. Kalil is a physician and Professor of Medicine in the Infectious Diseases Section, Department of Internal Medicine at the University of Nebraska Medical Center in Omaha, Nebraska. Dr. Kalil received his M.D. from the Federal University of Pelotas in Brazil and joined the University of Nebraska Medical Center faculty in 2003. He did his Internship and Internal Medicine Residency at the University of Miami/Jackson Memorial Hospital, Miami, Florida, and completed his Infectious Diseases and Critical Care Medicine Fellowships at the Massachusetts General Hospital (Harvard University, Boston, MA) and at the National Institutes of Health (NIH, Bethesda, MD), respectively. Dr. Kalil works as an attending clinician and a researcher at the University of Nebraska Medical Center. He is currently the Director of the Transplant Infectious Diseases Program at the University of Nebraska. Dr. Kalil has received numerous honors and awards, including the 2014 Distinguished Scientist Award and the 2012 Clinical Research Award. He is a member of a number of professional organizations, has been a peer-reviewer and associate editor for major medical journals, and has published three hundred PubMed indexed scientific articles. |
 |
The Modern Approach to the Diagnosis of Fungal Sepsis Coleman Rotstein, MD Professor, Division of Infectious Diseases, University of Toronto and Attending Physician at the University Health Network, Toronto, ON Canada Dr. Rotstein is Professor of Medicine in the Division of Infectious Diseases at the University of Toronto and Attending Physician at the University Health Network, Toronto, Ontario. His research interests have focused on infections in cancer patients. |
 |
Options for Difficult-To-Treat Gram-Negative Infections – What to Choose and When Matteo Bassetti, MD Head, Infectious Diseases Clinic, San Martino-IST University Hospital and Full Professor of Infectious Diseases of the University of Genoa, Genoa Italy Matteo Bassetti is Head of the Infectious Diseases Clinic of the Policlinico San Martino University Hospital in Genoa and Full Professor of Infectious Diseases of the University of Genoa, Italy. Dr Bassetti studied at the University of Genoa School of Medicine and continued his medical education at the Yale University School of Medicine, New Haven, USA with an Infectious Diseases fellowship. Dr Bassetti is president of the Italian Society of Anti-infective Therapy (SITA) and member of executive committee for the battle against antimicrobial resistance of the Italian Minister of Health (PNCAR). He is co-chair of the Intra-abdominal Infections Study Group of the International Society of Chemotherapy (ISC). He is member-elected (2018-2022) of International Council of the Immunocompromised Host Society (ICHS). From 2019 he is member of the council of International Sepsis Forum (ISF). He serves on the editorial board of several prestigious international journals. Author or co-author of 650 papers (H index 67; 19500 citations) published in International peer-review journals and several chapter’s book on antibiotic therapy, fungal infections, antimicrobial resistances, infections in immunocompromised patients and critically ill patients. |
|
Treating Invasive Candida Sepsis Eric Bow, MD Professor and Head, Section of Hematology/Oncology, Infectious Diseases Consultant, Health Sciences Centre, University of Manitoba, Winnipeg, MB Canada Dr. Bow is a Haematologist/Oncologist and Infectious Diseases physician trained in clinical microbiology (mycology) specializing in oncology and transplant infectious diseases. |
|
Considerations for the Treatment of HAP/VAP in Patients at High Risk of Mortality Ignacio Martin-Loeches, MD Consultant in Intensive Care Medicine, St James's Hospital and Professor at Trinity College, Dublin, Ireland Professor of Intensive Care Medicine Trinity College Dublin. |
|
Options for MRSA Infections – What to Choose and When Salman Qureshi, MD Staff Intensivist, McGill University Health Centre and Research Director, Meakins-Christie Laboratories; Associate Professor, Division of Experimental Medicine and Department of Medicine, McGill University Dr. Qureshi is a clinician-scientist at the McGill University Health Centre. He is an attending ICU physician and directs a basic research program that studies host genetic susceptibility to infection. |
 |
Vancomycin AUC for Serious MSRA Infections Tom Lodise, MD Clinical Pharmacist, Stratton VA Medical Center and Professor, Albany College of Pharmacy and Health Sciences, Albany NY, USA Thomas Lodise, Pharm.D., Ph.D., is a Professor at Albany College of Pharmacy and Health Sciences, Albany, New York. He is also an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York. |
|
Initiating, Escalating, De-escalating and Stopping Antibiotics in the ICU Patient Nick Daneman, MD Assistant Professor, Section of Infectious Diseases, Faculty of Medicine, University of Toronto and Scientist, Sunnybrooke Research Institute Dr. Nick Daneman is a clinician scientist in the division of infectious diseases at Sunnybrook Health Sciences Centre, is cross-appointed in the Institute of Health Policy Management and Evaluation, at the University of Toronto, and is an adjunct scientist at the Institute for Clinical Evaluative Sciences. He is supported by a Clinician Scientist salary award from the Canadian Institutes of Health Research. Using hospital, clinical trial, and population-based data sources, his research program aims to optimize the treatment and prevention of healthcare associated infection, with overlapping themes including antibiotic stewardship, critical care infections and C. difficile. The BALANCE research program has received a $2 million grant from CIHR aiming to determine the optimal treatment duration for blood stream infections in critically ill patients. |
 |
CAP Empiric Therapy and De-escalation Strategies Srinivas Murthy, MD Clinical Associate Professor, Pediatric Critical Care and Infectious Diseases Physician, BC Children’s Hospital, UBC Vancouver BC Canada Srinivas Murthy is a clinician and researcher at the University of British Columbia, he is board-certified in infectious diseases and critical care. His areas of interest are severe infections, innovative clinical trials, and infection prevention. |
|
Use of Immunoglobulin Therapy for Infection/Sepsis in the ICU Evangelos Giamarellos-Bourboulis, MD Professor, Internal Medicine and Infectious Diseases, Medical School of the National and Kapodistrian University, Athens Greece of Athens Evangelos J. Giamarellos-Bourboulis is Professor of Internal Medicine and Infectious Diseases at the Medical School of the National and Kapodistrian University of Athens since 2018.His main research contribution is immunomodulation in sepsis. |
|
HAP Empiric Therapy and De-escalation Strategies Andre Kalil, MD Professor, Department of Internal Medicine and Director, Transplant Infectious Diseases, University of Nebraska, Omaha Dr. Kalil is a physician and Professor of Medicine in the Infectious Diseases Section, Department of Internal Medicine at the University of Nebraska Medical Center in Omaha, Nebraska. Dr. Kalil received his M.D. from the Federal University of Pelotas in Brazil and joined the University of Nebraska Medical Center faculty in 2003. He did his Internship and Internal Medicine Residency at the University of Miami/Jackson Memorial Hospital, Miami, Florida, and completed his Infectious Diseases and Critical Care Medicine Fellowships at the Massachusetts General Hospital (Harvard University, Boston, MA) and at the National Institutes of Health (NIH, Bethesda, MD), respectively. Dr. Kalil works as an attending clinician and a researcher at the University of Nebraska Medical Center. He is currently the Director of the Transplant Infectious Diseases Program at the University of Nebraska. Dr. Kalil has received numerous honors and awards, including the 2014 Distinguished Scientist Award and the 2012 Clinical Research Award. He is a member of a number of professional organizations, has been a peer-reviewer and associate editor for major medical journals, and has published three hundred PubMed indexed scientific articles. |
 |
New Perspectives on Severe Influenza and Non-influenza Respiratory Virus Infections Nelson Lee, MDProfessor and Interim Director, Institute for Pandemics; Dalla Lana School of Public Health, University of Toronto Professor Nelson Lee MBBS, MD, MRCP(UK), FRCP(Lond.), FRCP(Edin.), FIDSA Interim Director, Institute for Pandemics Dalla Lana School of Public Health |
 |
Prolonged and Extended β-lactam Infusion for Critical Infections in ICU Jason Roberts, PhD Professor, University of Queensland and Consultant Clinical Pharmacist at the Royal Brisbane and Women’s Hospital, Brisbane Australia Professor Jason Roberts is a Clinical Pharmacist at Royal Brisbane and Women’s Hospital and an Australian National Health and Medical Research Council Practitioner Fellow at The University of Queensland. He is the Interim Director of the Herston Inf. |
 |
How to Use Procalcitonin in the ICU Gloria Vazquez-Grande, MD MSc Lecturer and Staff physician section of Critical Care Medicine at University of Manitoba. Dr. Gloria Vazquez Grande is an intensivist and early career investigator with a PhD in Medical Microbiology and Infectious diseases from University of Manitoba. Originally from Spain, came to Canada to pursue a career as a physician scientist. |
|
Therapeutic Drug Monitoring in the ICU Jason Roberts, PhD Professor, University of Queensland and Consultant Clinical Pharmacist at the Royal Brisbane and Women’s Hospital, Brisbane Australia Professor Jason Roberts is a Clinical Pharmacist at Royal Brisbane and Women’s Hospital and an Australian National Health and Medical Research Council Practitioner Fellow at The University of Queensland. He is the Interim Director of the Herston Inf |
 |
Clinical Management Guidelines for Pandemics: Are They Worth the Effort? Henry Masur, MD Senior Investigator and Chief, Critical Care Medicine, NIH Clinical Center Dr. Masur is the Chief of the Critical Care Medicine Department at the NIH Clinical Center. He has extensive experience developing guidelines for HIV, HCV, and COVID-19. |
|
Emerging Rapid Molecular Microbiologic Diagnostic Technologies Donna Wolk, PhD Division Chief, Molecular and Microbial Diagnostics and Development, Geisinger Medical Center and Director of the Infectious Disease Research Laboratory, Weis Research Center Dr. Wolk serves as the Division Director for Molecular and Microbial Diagnostics and Development for Geisinger Health and is a Clinical Professor. Shravan Kethireddy, MD Associate ICU Attending Physician, Cleveland Clinic, Cleveland, OH USA Board certified physician in Infectious Diseases, Critical Care Medicine and Clinical Informatics. Currently Associate Staff Respiratory Institute Cleveland Clinic. |
 |
Antimicrobials in Critical Illness: How Fast is Fast Enough? Mike Klompas, MD Professor, Population Medicine, Harvard Medical School; Hospital Epidemiologist and ID Consultant, Brigham and Women’s Hospital, Boston MA, USA Dr. Michael Klompas is an Infectious Disease physician and the Hospital Epidemiologist at Brigham and Women’s Hospital in Boston as well as Professor of Population Medicine in Harvard Medical School. |
 |
Antimicrobials in Sepsis and Septic Shock: How Fast is Too Fast? Chris Seymour, MDAssociate Professor of Critical Care and Emergency Medicine at the University of Pittsburgh School of Medicine; core faculty, Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center in the Department of Critical Care (focus on Program on Critical Care Health Policy) Dr. Seymour is an Associate Professor of Critical Care and Emergency Medicine at the University of Pittsburgh School of Medicine. He is a faculty member in the CRISMA Center and Associate Editor at JAMA. |
 |
Primer on Coronavirus Infections in Humans Sylvain Lother, MD Clinical Instructor, Sections of Infectious Diseases and Critical Care Medicine, University of Manitoba, Winnipeg MB Canada Dr. Lother is a Critical Care and Infectious Disease physician at the University of Manitoba. He is an early career clinician-scientist with interest in clinical trials for Covid-19 and CAP |
|
Friday, February 25, 2022 |
|
|
SARS Robert Fowler, MD Professor, Department of Critical Care Medicine, University of Toronto and Attending Intensivist, Sunnybrooke Medical Centre, Toronto ON Canada
Rob Fowler is a critical care physician and Barrie Fairley Professor at the University of Toronto, chief of the trauma-critical care program at Sunnybrook Health Sciences Centre and and Chair of the Canadian Critical Care Trials Group.
|
 |
MERS Yaseen Arabi, MD Professor and Chairman, Intensive Care Department, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia He is currently the Chairman of the Intensive Care Department, Medical Director, Respiratory Services, Professor, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center. |
 |
Through a Glass Darkly: Measuring Prognosis in COVID-19 Ryan Maves, MD Professor, Infectious Diseases and Anesthesiology, Wake Forrest School of Medicine, Winston-Salem, NC USA Dr. Ryan Maves is a Professor of Medicine and Anesthesiology at the Wake Forest School of Medicine. His clinical work focuses on transplant ID as well as medical and cardiothoracic intensive care. |
 |
COVID-19: The Pediatric Perspective Angela Bates, MD Associate Clinical Professor, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, AB Canada Currently a PCICU intensivist and PCICU ID lead in a busy tertiary post-op cardiac unit, as well as the medical director of the pediatric PHTN program. Lead initiative is the prevention of invasive infections in post-operative pediatric patients. |
| |
Co-infections and Complications Josh Douglas, MD Clinical Instructor, Infectious Diseases and Critical Care Medicine, University of British Columbia and Head, Infection Control, Lion’s Gate Hospital, Vancouver BC Canada Clinical Assistant Professor of Medicine, Department of Infectious Diseases, University of British Columbia. Division Head of Critical Care, Vancouver Coastal Community of Care |
| |
COVID-19 Vaccine Efficacy and Disease Severity among Immunocompromised Patients Kelly MacDonald, MD FRCPC H.E. Sellers Research Chair Professor, Section of Infectious Diseases Departments of Medicine, Medical Microbiology & Immunology Max Rady College of Medicine University of Manitoba Adjunct Scientist (Research Lab) JC Wilt Research Centre Public Health Agency of Canada |
| |
Respiratory Injury and Mechanical Support Salman Qureshi, MD Staff Intensivist, McGill University Health Centre and Research Director, Meakins-Christie Laboratories; Associate Professor, Division of Experimental Medicine and Department of Medicine, McGill University Dr. Qureshi is a clinician-scientist at the McGill University Health Centre. He is an attending ICU physician and directs a basic research program that studies host genetic susceptibility to infection. |
| |
The Nature of Extra-Pulmonary Organ Injury and Support Ken Wood, DO Staff Intensivist, Executive VP and Chief Clinical Officer Lifespan System, Professor of Medicine Brown University Alpert School of Medicine, Providence, RI USA Dr. Wood is a Professor of Medicine at the Warren Alpert Medical School at Brown University and Chief Clinical Officer for the Lifespan Health System which is the Academic Medical System for the Medical School |
| |
Co-infections and Complications Josh Douglas, MD Clinical Instructor, Infectious Diseases and Critical Care Medicine, University of British Columbia and Head, Infection Control, Lion’s Gate Hospital, Vancouver BC Canada Clinical Assistant Professor of Medicine, Department of Infectious Diseases, University of British Columbia. Division Head of Critical Care, Vancouver Coastal Community of Care |
 |
Heparin Therapy of COVID-19…Theory and Data Ryan Zarychanski, MD Associate Professor, Sections of Hematology and Critical Care Medicine and Clinician-Scientist at the University of Manitoba, Winnipeg Canada Dr. Zarychanski is a Critical Care physician, Hematologist, and Clinician-Scientist at the University of Manitoba and CancerCare Manitoba. His research focuses on the hematologic aspects of critical illness where he leads several international randomized trials in the fields of COVID-19, sepsis and transfusion medicine. |
 |
Inpatient Passive Immune Therapy for COVID-19 John Beigel, MD Associate Director, Clinical Research, Division of Microbiology and Infectious Diseases National Institute for Allergy and Infectious Diseases (NIAID), NIH Washington, DC USA Dr. John Beigel is at the US National Institute of Allergy and Infectious Diseases (NIAID). He attended the Medical College of Ohio, complete residency at the University of Cincinnati, a fellowship in Critical Care Medicine at the National Institutes |
| |
Immune Modulation Therapy of Severe COVID-19 Srinivas Murthy, MD Clinical Associate Professor, Pediatric Critical Care and Infectious Diseases Physician, BC Children’s Hospital, UBC Vancouver BC Canada Srinivas Murthy is board-certified in infectious diseases and critical care. His areas of interest are severe infections, innovative clinical trials, and infection prevention. |
| |
Inpatient Antiviral Therapy for COVID-19 John Beigel, MD Associate Director, Clinical Research, Division of Microbiology and Infectious Diseases National Institute for Allergy and Infectious Diseases (NIAID), NIH Washington, DC USA Dr. John Beigel is at the US National Institute of Allergy and Infectious Diseases (NIAID). He attended the Medical College of Ohio, complete residency at the University of Cincinnati, a fellowship in Critical Care Medicine at the National Institutes |
 |
COVID-19: Where We’ve Been and Where We’re Going Amesh Adalja, MD Senior Scholar at the Johns Hopkins Center for Health Security, Adjunct Assistant Professor at the Johns Hopkins Bloomberg School of Public Health Dr. Adalja is a Senior Scholar at the Johns Hopkins Center for Health Security and a practicing infectious disease, critical care, and emergency medicine doctor. |